Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

283 results about "Lupus nephritis" patented technology

Lupus nephritis is kidney inflammation caused by systemic lupus erythematosus (SLE or lupus). SLE is an autoimmune disease—a disorder in which the body's immune system attacks the body's own cells and organs.

Lupus nephritis image segmentation method, lupus nephritis image segmentation device, medium and equipment

The invention discloses a lupus nephritis image segmentation method and device, a medium and equipment, and relates to the technical field of image segmentation. In order to solve the technical problem of inaccurate segmentation of lupus nephritis images due to local optimum, the invention provides a method. The method comprises the following steps: obtaining a to-be-segmented lupus nephritis gray image and a corresponding two-dimensional histogram; searching a group of segmentation thresholds on the two-dimensional histogram by using an improved rime algorithm; the improved rime algorithm comprises the steps that a foraging-storage optimization stage parallel to an original rime algorithm optimization stage is added, and the original rime algorithm optimization stage and the foraging-storage optimization stage are executed randomly; and performing threshold segmentation on the to-be-segmented lupus nephritis grayscale image based on the segmentation threshold. According to the method, different optimization stages are executed through random lines, so that the optimization process is prevented from falling into a fixed search mode, the algorithm is prevented from being stopped near a certain local optimal solution, and the opportunity of finding a threshold which enables lupus nephritis image segmentation to be more accurate is increased.
Owner:BIG DATA & INFORMATION TECH RES INST OF WENZHOU UNIV

Method for constructing Ddx58-R109C point mutation mouse model and application of Ddx58-R109C point mutation mouse model

The invention discloses a method for constructing a Ddx58-R109C point mutation mouse model by using a CRISPR / Cas9 gene editing technology and an application of the Ddx58-R109C point mutation mouse model. The method comprises the following steps: (1) target construction: searching a CDS region of a Ddx58 gene, determining an exon part, and determining a gene mutation site; (2) obtaining a fertilized egg, and injecting Cas9mRNA, gRNA and donor oligo into the fertilized egg of the C57BL / 6J mouse together in vitro through a microinjection technology to obtain an F0-generation hybrid mouse; (3) mating the F0-generation hybrid mouse with the wild type mouse to obtain an F1-generation mouse; (4) the F1-generation heterozygous mice which are identified to be positive are subjected to mating, and homozygous Ddx58-R109C mutant type and wild type mice can be obtained by breeding obtained offspring; (5) phenotypic analysis shows that Ddx58-R109C point mutation mice can have pathological changes of systemic lupus erythematosus and lupus nephritis; the invention can provide an effective research approach and method for researchers to deeply explore the action mechanism of Ddx58-R109C mutation in diseases, and has important significance for explaining the pathogenesis of systemic lupus erythematosus and researching and developing targeted therapeutic drugs.
Owner:NANJING GENERAL HOSPITAL NANJING MILLITARY COMMAND P L A

Method for constructing differential diagnosis model of lupus nephritis and membranous nephropathy

The invention discloses a method for constructing a differential diagnosis model for lupus nephritis and membranous nephropathy, and belongs to the technical field of intelligent medical treatment. The modeling method comprises the following steps: S1, respectively collecting flow cytometry detection data of lupus nephritis patients and healthy control personnel; s2, performing data cleaning and conversion on the flow cytometry detection data, and converting non-numerical features into digits; carrying out implication on the missing value by adopting a k nearest neighbor algorithm from an implication packet; s3, random sampling is carried out on the cleaned and converted data set, and samples are divided into a training set and a verification set according to the proportion of 7: 3; s4, dividing a training subset and a test set from the training set, and iteratively selecting the types of cells incorporated into the constructed model as pDC, CD4T, effector CD4T, Th2, CD8T, CD38 + HLA-DR + CD8T, and CD38 + PD-1 + CD8T by adopting an RFE method, wherein the types of the cells incorporated into the constructed model are pDC, CD4T, effector CD4T, Th2, CD8T, CD38 + HLA-DR + CD8T and CD38 + PD-1 + CD8T; and S5, performing a classification task by adopting TabPFNClassifier, performing training from features selected from the training data set, then evaluating the performance of the model, performing model training by utilizing detection data, and performing evaluation to construct a lupus nephritis prediction model with high accuracy.
Owner:BEIJING HOSPITAL

Flavonoid active fraction of an abelmoschi corolla, preparation method and application thereof

The invention relates to a flavonoid active fraction of an Abelmoschi corolla, a preparation method and an application thereof, and belongs to the field of traditional Chinese pharmaceutics. A high-purity Abelmoschi corolla flavonoid active fraction is prepared, which is found to have better therapeutic activity for kidney disease, and especially have a significant therapeutic effect for diabetic kidney disease and lupus nephritis, or contrast-induced kidney injury and eye diseases. Meanwhile, the Abelmoschi corolla flavonoid active fraction described in the invention also has good safety.
Owner:SUZHONG PHARMACEUTICAL GROUP CO LTD +1

Application of intervening basophilic granulocyte EXOSC3 in preparation of medicine for preventing or treating lupus nephritis

The invention belongs to the technical field of biological medicines, and discloses an application of intervening basophilic granulocyte EXOSC3 in preparation of a medicine for preventing or treating lupus nephritis, which comprises knocking down or knocking out the expression of EXOSC3. The invention finds that the expression of EXOSC3 is enhanced after basophilic granulocyte activation, and the expression is reduced after activation inhibition. After the EXOSC3 of the basophilic granulocyte is knocked down, the expression levels of inflammatory factors IL-4, IL-6 and IL-13 of the basophilic granulocyte are obviously reduced. After the basophilic granulocyte knock-down EXOSC3 and T cells are co-cultured, the activation level of the T cells is obviously reduced. After the basophilic granulocytes knocking down the Exosc3 are adoptively transferred into a lupus mouse body, the kidney pathology is obviously improved. The invention proves that the knock-down basophilic granulocyte EXOSC3 can obviously inhibit the activation of the basophilic granulocyte EXOSC3 and improve the kidney pathology of lupus mice, thereby providing a new thought for the treatment of basophilic granulocyte activation-mediated lupus diseases.
Owner:AFFILIATED HOSPITAL OF GUANGDONG MEDICAL UNIV

Methods of determining whether a subject suffering from lupus nephritis (LN) will achieve a response with an induction therapy

Systemic lupus erythematosus (SLE) is an autoimmune disease in which circulating immune complexes can cause different types of glomerulonephritis, according to immune deposits and to the type of glomerular cell injury. Proliferative lesions represent the most severe form of lupus nephritis (LN) and often lead to kidney failure and death. Mucosal-associated invariant T (MAIT) are a subset of innate-like T cells that recognize microbial-derived ligands from the riboflavin synthesis pathway. Now the inventors analyzed the phenotype and function of peripheral blood MAIT cells by flow cytometry in 26 patients with LN and in a control group of 16 healthy volunteers. The inventors found that MAIT cell frequencies are markedly reduced in blood of LN patients. More particularly, among LN patients, baseline MAIT cell frequency, Ki-67 expression evaluating proliferative activity and granzyme B production measuring cytotoxicity represent promising prognostic factors of renal response one year after induction therapy. In conclusion, the inventors showed that baseline frequency and cytotoxic profile of MAIT cells may represent a promising prognostic factor of renal remission one year after induction therapy.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +3

Circular RNA encoding cars and the use thereof

Provided is a circular RNA encoding CARs and the use thereof to create immune cells that target specific diseases, e. g., lymphoma, multiple myeloma and leukemia and auntoimmune diseases, such as systemic lupus erythematousus, lupus nephritis and myasthenia gravis.
Owner:THERORNA SHANGHAI CO LTD

Compositions and methods of treating lupus nephritis

The present disclosure provides methods for treating lupus nephritis in an individual that has lupus. In some embodiments, the methods comprise administering to the individual an effective amount of a type II anti-CD20 antibody. In other aspects, the present disclosure provides methods for treating membranous nephropathy.
Owner:GENENTECH INC

Biomarker for diagnosing systemic lupus erythematosus and lupus nephritis and application thereof

The invention discloses a biomarker for diagnosing systemic lupus erythematosus and lupus nephritis and application of the biomarker, and relates to the technical field of biological medicines. The biomarker is an ISG15hiCD16 < + > mononuclear cell. According to the application disclosed by the invention, the ISG15hiCD16 + mononuclear cell subpopulation is found to be obviously increased in an SLE (systemic lupus erythematosus) patient. The invention also finds that the expression level of the ISG15hiCD16 + mononuclear cell subpopulation is positively correlated with the disease activity of the SLE patient, and the expression level of the ISG15hiCD16 + mononuclear cell subpopulation of the SLE patient with the kidney enduring expression is obviously higher than that of the SLE patient without the kidney enduring expression. The working characteristic curve analysis of a subject shows that the ISG15hiCD16 + mononuclear cell subset has better sensitivity and specificity for diagnosing the SLE and the LN, and has important significance for clinical auxiliary diagnosis of the SLE and the LN and illness state evaluation.
Owner:THE FIRST HOSPITAL OF LANZHOU UNIV

Membrane nephropathy marker and application thereof

The invention provides an application of a reagent for detecting an effector CD4 + T cell in peripheral blood of a subject in preparation of a product for diagnosing membranous nephropathy, lupus nephritis or ANCA-related vasculitis. The invention also provides an application of the effector CD4 + T cell in peripheral blood in preparation of a diagnostic model for diagnosing membranous nephropathy, lupus nephritis or ANCA-related vasculitis. The marker is detected through flow cytometry, and the result shows that the Ejector CD4 + T cell is remarkably increased in a patient with membranous nephropathy, can effectively distinguish membranous nephropathy from healthy control (verification set AUC 0.8098), can assist in identifying membranous nephropathy, lupus nephritis (verification set AUC 0.8686) and ANCA-related vasculitis (verification set AUC 0.8968), and the level of the Ejector CD4 + T cell is related to whether membranous nephropathy is difficult to treat or not.
Owner:THE FIRST MEDICAL CENT CHINESE PLA GENERAL HOSPITAL

Nucleic acids for inhibiting expression of complement factor b (CFB) in a cell

The invention relates to nucleic acid products that interfere with complement factor B (CFB) gene expression or inhibit its expression. The nucleic acids are preferably for use in the prophylaxis or treatment of complement associated diseases, disorders or syndromes, particularly C3 glomerulopathy (C3G), paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), lupus nephritis, IgA nephropathy (IgA N), myasthenia gravis (MG), and primary membranous nephropathy.
Owner:SILENCE THERAPEUTICS GMBH

Marker for lupus nephritis and application thereof

The invention discloses a lupus nephritis marker and application thereof, and belongs to the technical field of biomarkers. The marker for the lupus nephritis, disclosed by the invention, comprises one or more of CD8, CD38 and PD-1. By detecting specific cell surface markers in patient blood, early diagnosis of LN is assisted in a minimally invasive mode, and based on deep comparative analysis of LN patients and healthy people, the specificity and sensitivity of the biomarkers in LN diagnosis are ensured through screening of the biomarkers. In the aspect of differential diagnosis, a clinician is assisted to distinguish LN from other types of kidney diseases, such as membranous nephropathy (MN) and anti-neutrophil cytoplasm antibody related vasculitis (AAV), by analyzing specific biomarker modes of different nephropathy. The dependence on kidney puncture is reduced, related potential risks and inconvenience are avoided, and meanwhile more accurate and timely diagnosis is provided for an SLE patient.
Owner:BEIJING HOSPITAL

Double-stranded siRNA analogue for inhibiting MASP2 expression as well as preparation method and application of double-stranded siRNA analogue

The present invention relates to a double-stranded siRNA analogue for inhibiting expression of mannan-binding lectin-related serine protease 2 (MASP2), and a preparation method and use thereof, the double-stranded siRNA analogue can inhibit expression of MASP2, and is used for preventing and / or treating MASP2-related diseases and symptoms, such as MASP2-related diseases and disorders. The diseases and symptoms comprise IgA nephropathy, membranous nephropathy, lupus nephritis, thrombotic microangiopathy, systemic lupus erythematosus and the like.
Owner:SHENZHEN SALUBRIS PHARMA CO LTD

Preparation of monoclonal antibody 8a12 against sema7a and its therapeutic effect on lupus nephritis

The application provides a preparation of a sema7A monoclonal antibody 8A12 and a treatment effect of the sema7A monoclonal antibody 8A12 on lupus nephritis, wherein the CDR-H1 of the heavy chain variable region of the monoclonal antibody 8A12 is an amino acid sequence shown in SEQ ID No. 1, the CDR-H2 of the heavy chain variable region is an amino acid sequence shown in SEQ ID No. 2, and the CDR-H3 of the heavy chain variable region is an amino acid sequence shown in SEQ ID No. 3; the CDR-L1 of the light chain variable region of the monoclonal antibody 8A12 is an amino acid sequence shown in SEQ ID No. 4, the CDR-L2 of the light chain variable region is an amino acid sequence shown in SEQ ID No. 5, and the CDR-L3 of the light chain variable region is an amino acid sequence shown in SEQ ID No. 6. The monoclonal antibody 8A12 can effectively inhibit the expression up-regulation of IL-1beta, TNF-alpha and IL-6 caused by Sema7A recombinant protein, can effectively inhibit the macrophage inflammatory response induced by Sema7A, and can continuously and effectively reduce serum anti-double-stranded DNA antibodies and kidney damage of lupus mice. The monoclonal antibody 8A12 can be used for preparing a pharmaceutical composition for preventing and / or treating systemic lupus erythematosus and / or lupus nephritis thereof.
Owner:SUZHOU UNIV

Use of phlorizin in the treatment and / or prevention of lupus nephritis

The application of phlorizin in the medicine for treating and / or preventing lupus nephritis, the molecular formula of phlorizin is C 21 H 24 O 10 , the application promotes the differentiation of regulatory T cells (Treg) by applying phlorizin to up-regulate the PI3K / Akt signal pathway, thereby reducing the symptoms of lupus nephritis, and provides an effective treatment method with less side effects. In the application, the traditional Chinese medicine monomer phlorizin can effectively promote the differentiation of Treg cells, and compared with compound traditional Chinese medicine, the use of single component has more advantages in drug efficacy control and efficacy evaluation. In addition, phlorizin is widely sourced, low in cost and non-toxic, and is very suitable for long-term treatment of lupus nephritis.
Owner:ZHEJIANG CHINESE MEDICAL UNIVERSITY

N-acyl-{4-[(4-aryl-phenyl)sulfonylmethyl]piperidine} compounds and their therapeutic use

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain N-acyl-{4-[(4-aryl-phenyl)sulfonylmethyl]piperidine} compounds of the following formula (collectively referred to herein as NASMP compounds) that are useful, for example, in the treatment of disorders (e.g., diseases) including, e.g., multiple myeloma, diffuse large B-cell lymphoma, acute myeloid leukemia, eosinophilic leukemia, glioblastoma, melanoma, ovarian cancer, chemotherapy resistant cancer, radiation resistant cancer, inflammatory arthritis, rheumatoid arthritis, psoriatic arthritis, psoriasis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus (SLE), lupus nephritis, asthma, chronic obstructive pulmonary disease (COPD), Hidradenitis suppurativa, autoimmune hepatitis, etc. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.
Owner:MODERN BIOSCI LTD

Solid forms of a KV1.3 potassium shaker channel blockers and method of using the same

PCT designated stage expiredWO2025029769A1Nervous disorderOrganic chemistryBenzoic acidGlutaric acid
Solid forms of compound of (2R)-1-[4-[(R)-amino(5-chloro-2-hydroxy-4-methylphenyl)methyl]piperidin-1-yl]-2,3-dihydroxypropan-1-one are described. The solid form may be a pharmaceutically acceptable salt of the compound. The salt may be a carboxylic acid salt, such as a benzoic acid salt, a cinnamic acid salt, or a glutaric acid salt. Pharmaceutical compositions comprising the same and method of using the same in treating a condition such as psoriasis, rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, atopic dermatitis, and alopecia areata are also described.
Owner:ELI LILLY & CO

Treatment of lupus nephritis with Anti-type i inf receptor antibody anifrolumab

The disclosure relates to methods and compositions for the treatment of lupus nephritis (LN) with anti-type I IFN receptor inhibitor antibody Anifrolumab. Results of clinical trials with intravenous and subcutaneous administration of Anifrolumab. Identification of markers for LN and delivery devices and pre-filled syringe for administration of Anifrolumab.
Owner:ASTRAZENECA AB

A biomarker for evaluating progression of systemic lupus erythematosus to lupus nephritis, a prediction model and application thereof

The application discloses a kind of biomarkers for evaluating systemic lupus erythematosus to lupus nephritis progression, prediction model and application, belong to lupus nephritis prediction technical field.The application provides a kind of for evaluating systemic lupus erythematosus to lupus nephritis progression prediction model, the prediction model is according to the ratio of biomarker CD8 / CD4 and the κ / λ ratio of naive B cell, carries out binary Logistic regression analysis, obtains LogitP value, by comparing the high and low of the LogitP value and critical value 0.66938, predicts systemic lupus erythematosus to lupus nephritis progression situation.The prediction model constructed in the application aims to identify the individuals in lupus patients who may develop into lupus nephritis.This innovative model not only provides important guidance in the diagnosis, prognosis prediction and efficacy evaluation of the disease, but also provides a new perspective for the clinical management of lupus nephritis.
Owner:THE FIRST MEDICAL CENT CHINESE PLA GENERAL HOSPITAL

Diagnostic marker for ANCA-related vasculitis

The invention discloses a diagnostic marker for ANCA (Angiovasculitis) related vasculitis. It is found for the first time that the CD19 + CD38 + CD27-CD24 + cell can be used as the diagnosis marker of ANCA related vasculitis, and the diagnosis efficiency is high; in addition, it is found that the CD19 + CD38 + CD27-CD24 + cells can remarkably distinguish ANCA related vasculitis and membranous nephropathy or ANCA related vasculitis and lupus nephritis, a new direction is provided for diagnosis and subsequent treatment of ANCA related vasculitis, and the application has wide application prospects clinically.
Owner:BEIJING HOSPITAL

Lupus nephritis condition monitoring system based on dynamic change of TWEAK and CD163

The invention relates to the field of medical care informatics, and discloses a lupus nephritis condition monitoring system based on TWEAK and CD163 dynamic change, which comprises a data adaptation gateway module, a data rationality arbitration engine, a time sequence regularization engine module, a high-order feature extraction engine module and a risk layering module, the time sequence regularization engine module switches an interpolation or smoothing algorithm based on a qualitative result of the data rationality arbitration engine and a time domain where a data point is located so as to generate a continuous time function. Through the information processing architecture, the technical problem that sparse asynchronous original medical data is prone to being affected by outlier pollution and end point distortion is solved, and the accuracy of data processing is improved. The system reconstructs discrete data snapshots into continuous mathematical objects, provides a stable and analyzable technical basis for subsequent extraction of interpretable high-order dynamic features, and improves the credibility of clinical decision support.
Owner:南昌大学第一附属医院

RNAi agent for inhibiting complement factor B (CFB) expression, pharmaceutical composition thereof, and method of use

This disclosure relates to RNAi agents capable of inhibiting complement factor B (CFB) gene expression. Pharmaceutical compositions containing CFB RNAi agents and methods of use thereof are also disclosed. The CFB RNAi agents disclosed herein may be conjugated to a targeted ligand containing an N-acetyl-galactosamine ligand to facilitate in vivo delivery to hepatocytes. RNAi agents can be used in methods of treating diseases, disorders, or conditions partially mediated by CFB gene expression, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex-mediated membrane proliferative glomerulonephritis (IC-MPGN), lupus nephritis (LN), anti-glomerular basement membrane antibody disease (anti-GBM), ischemia-reperfusion injury and T-cell-mediated rejection in kidney transplantation (TCMR), anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, age-related macular degeneration (AMD) including early and / or intermediate-stage AMD, geographic atrophy (GA), glaucoma, Doyne honeycomb retinal dystrophy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), pre-eclampsia, rheumatoid arthritis (RA), and / or other complement-mediated disorders.
Owner:ARROWHEAD PHARMACEUTICALS INC

Compositions and methods of treating lupus nephritis

The invention provides methods for treating or delaying progression of lupus nephritis in an individual that has lupus. In some embodiments, the methods comprise administering to the individual an effective amount of a type II anti-CD20 antibody. The invention also provides methods for treating or delaying progression of rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) in an individual. In some embodiments, the methods comprise administering an effective amount of an anti-CD20 antibody.
Owner:GENENTECH INC

Substituted pyrrolidine-2-carboxylic acid derivatives as cgas inhibitors

[0366] Compounds of Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the cGAS pathway, such as autoimmune disorders including Aicardi-Goutieres Syndrome (AGS), Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Scleroderma, Sjogren's Syndrome, Inflammatory Myopathies, Hidradenitis Supperativa (HS), Parkinson's Disease, Rheumatoid Arthritis, Ulcerative Colitis and Crohn's Disease, formula (II) wherein Ra, (A), R1 and R2, are defined herein.
Owner:JANSSEN PHARMA NV

Traditional Chinese medicine compound granules for treating lupus nephritis and preparation method thereof

The invention belongs to the technical field of traditional Chinese medicine preparations, and particularly relates to traditional Chinese medicine compound granules for treating lupus nephritis and a preparation method thereof. The formula of the traditional Chinese medicine compound granules comprises 25-35 parts of astragalus membranaceus, 8-12 parts of angelica sinensis, 8-12 parts of salvia miltiorrhiza, 25-35 parts of artemisia apiacea, 12-18 parts of caulis sinomenii, 25-35 parts of centella asiatica, 25-35 parts of raw malt and 25-35 parts of euonymus alatus. The medicinal materials are subjected to water extraction, extracting solutions are combined and concentrated into extract, maltodextrin, microcrystalline cellulose and soluble starch are selected as auxiliary materials to be dried and granulated, and the prepared traditional Chinese medicine compound granules are low in fine powder proportion, high in hardness and short in dissolution time. By adopting the dosage form of granules, not only are the characteristics of quick absorption and quick action of the decoction maintained, but also the defects of inconvenience in decoction, large dosage and easiness in mildewing during temporary use of the decoction are overcome, and the curative effect is remarkably improved.
Owner:HANGZHOU TRADITIONAL CHINESE MEDICINE HOSPITAL (HANGZHOU TRADITIONAL CHINESE MEDICINE HOSPITAL AFFILIATED TO ZHEJIANG UNIV OF TRADITIONAL CHINESE MEDICINE)

Protocol for treatment of lupus nephritis

To provide a method for treating a proteinuric kidney disease.SOLUTION: There is provided a method comprising administering a predetermined daily dosage of effective amounts of voclosporin over a projected treatment period of at least 24 weeks. The method further comprises: (a) assessing an estimated Glomerular Filtration Rate (eGFR) of a subject at at least a first time point and a second time point on different days within the treatment period; and (b) (i) when the eGFR of the subject decreases by more than a target % to below a predetermined value between the first and second time points, reducing the daily dosage by units of 7.9 mg BID or discontinuing the administration of voclosporin to the subject; (ii) when the eGFR of the subject decreases by less than the target % between the first and second time points, continuing to administer the same predetermined daily dosage of voclosporin to the subject.SELECTED DRAWING: Figure 1
Owner:AURINIA PHARMACEUTICALS INC

Compositions and methods useful in the treatment of autoimmune disease

The present disclosure relates to methods and compositions for the treatment of a mammalian subject suffering from lupus the method comprising, administering to said subject a therapeutically effective amount of an orthogonal CAR-T cell directed against a B-cell antigen in combination with an engineered orthogonal IL2 ligand that selectively activates orthogonal CAR T cell expressing an engineered orthogonal CD122 receptor. In some embodiments, the lupus is systemic lupus erythramatosis (SLE). In some embodiments, the lupus is lupus nephritis. In some embodiments the subject suffering from lupus is also suffering from cytopenia. In some embodiments the methods are practiced in the absence of prior lymphodepletion of the subject.
Owner:SYNTHEKINE INC